Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-12-19
2006-12-19
Ulm, John (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07151165
ABSTRACT:
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the G-protein coupled receptor family, referred to as IGS4-family. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides, to a vector containing said polynucleotides, a host cell containing such vector and transgenic animals where the IGS4-gene is either overexpressed, misexpressed, underexposed or suppressed (knock-out animals). The invention further relates to a method for screening compounds capable to act as an agonist or an antagonist of said G-protein coupled receptor family IGS4 and the use of IGS4 polypeptides and polynucleotides and agonists or antagonists to the IGS4 receptor family in the treatment of PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourett's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension—e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynand's disease, kidney disease—e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophagal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers—e.g. gastric ulcer, diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders, among others and diagnostic assays for such conditions. Preferred uses of the invention relate to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid and/or also to lung diseases, immunological diseases and disorders of the genitourinary system. The invention also relates to the identification of the cognate ligand of the IGS4 polypeptides of the invention. High affinity binding to said IGS4 polypeptides is found for the neuropeptides known as neuromedin U.
REFERENCES:
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5482835 (1996-01-01), King et al.
patent: 6461836 (2002-10-01), Elshourbagy et al.
patent: 6599718 (2003-07-01), Liu et al.
patent: WO90/01330 (1990-02-01), None
patent: WO99/55732 (1999-11-01), None
patent: WO00/22131 (2000-04-01), None
patent: WO00/31258 (2000-06-01), None
patent: WO 01/44297 (2001-06-01), None
GenBank Accession No.: F07531, (2 pages), Feb. 1995.
GenBank Accession No.: R13353, (2 pages), Apr. 1995.
GenBank Accession No.: R13890, (2 pages), Apr. 1995.
GenBank Accession No.: H11359, (2 pages), Jun. 1995.
GenBank Accession No.: AQ019411, (2 pages), Jun. 1998.
GenBank Accession No.: AQ015065, (2 pages), Jun. 1998.
GenBank Accession No.: N45474, (2 pages), Feb. 1996.
GenBank Accession No.: W61169, (2 pages), May 1996.
Accession No.: G20615, (2 pages), 1996.
GenBank Accession No.: AI432384, (2 pages), Feb. 1999.
GenBank Accession No.: W61131, (2 pages), May 1996.
GenBank Accession No.: AI023570, (2 pages), Jun. 1988.
GenBank Accession No.: F01358, (2 pages), Feb. 1995.
GenBank Accession No.: F03770, (2 pages), Feb. 1995.
GenBank Accession No.: Z38158, (2 pages), Oct. 1994.
Accession No.: G05725, (2 pages), 1995.
GenBank Accession No.: R40869, (2 pages), May 1995.
GenBank Accession No.: R37725, (2 pages), May 1995.
GenBank Accession No.: H11333, (2 pages), Jun. 1995.
GenBank Accession No.: AQ078563, (2 pages), Aug. 1998.
International Search Report for PCT/EP00/09584.
C.P. Tan et al., “Cloning and Characterization of a Human and Murine T-Cell Orphan G-Protein-Coupled Receptor Similar to the Growth Hormone Secretagogue and Neurotensin Receptors”, Genomics, vol. 52, pp. 223-229, Jun. 1998.
Takeda Chemical Ind. Ltd., “DNA Encoding Human Neurotensin Receptor Protein Useful for Screening for Antagonists Used to Treat Parkinson's Disease, Depression, Dementia, Retrograde Oesophagitis, Ulcers”, Patent Abstracts of Japan No. JP 08143597, Jun. 4, 1996.
Doe Joint Genome Institute “Sequencing of Human Chromosome 5”, pp. 1-5, Aug. 1995 (Abstract).
L. Hillier, et al., “yy59b04.r1 Homo Sapiens cDNA Clone” 277807 5' The WashU-Merck EST Project, pp. 1-2, Feb. 1996. (Abstract).
L. Hillier et al., “ zd31a03.r1 Soares Fetal Heart NbHH19W Homo Sapiens cDNA Clone,” 342220 5' The WashU-Merck EST Project, p. 1, Sep. 1996.
L. Hillier et al., “ym13d04.r1 Homo Sapiens cDNA Clone”, 47842 5' The WashU-Merck EST Project, pp. 1-2, Jul. 1995.
K.K. McKee et al., “Cloning and Characterization of two Human G Protein-Coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors”, Genomics, vol. 46, pp. 426-434, 1997.
N. Vita et al., “Cloning and Expression of a Complementary DNA Encoding a High Affinity Human Neurotensin Receptor”, FEBS Letters, vol. 317, No. 1,2, pp. 139-142, Feb. 1993.
N. Vita et al., “Neurotensin is an Antagonist of the Human Neurotensin NT2Receptor Expressed in Chinese Hamster Ovary Cells”, European Journal of Pharmacology, vol. 360, pp. 265-272, 1998.
A.D. Howard et al. “A Receptor in Pituitary and Hypothalamus that Functions in Growth Hormone Release”, Science, vol. 273, (5277): 974-977, Aug. 1996.
M. Hosoya et al., “Identification and Functional Characterization of a Novel Subtype of Neuromedin U Receptor”, The Journal of Biological Chemistry, vol. 275, pp. 29528-29532, Sep. 2000.
P.G. Szekeres et al., “Neuromedin U is a Potent Agonist at the Orphan G Protein-Coupled Receptor FM3”, The Journal of Biological Chemistry, vol. 275, pp. 20247-20250, Jul. 2000.
R. Fujii et al., “Identification of Neuromedin U as the Cognate Ligand of the Orphan G Protein-Coupled Receptor FM-3”, The Journal of Biological Chemistry, vol. 275, pp. 21068-21074, Jul. 2000.
R. Raddatz et al., “Identification and Characterization of Two Neuromedin U Receptors Differentially Expressed in Peripheral Tissues and the Central Nervous System,” The Journal of Biological Chemistry, vol. 275, pp. 32452-32459, Oct. 2000.
L. Shan et al., “Identification of a Novel Neuromedin U Receptor Subtype Expressed in the Central Nervous Sytem,” The Journal of Biological Chemistry, vol. 275, pp. 39482-39486, Dec. 2000.
A.D. Howard et al., “A Receptor in Pituitary and Hypothalamus that Functions in Growth Hormone Release”, Science, vol. 273, (5277):974-977, Aug. 1996.
J. Domin et al., “Neuromedin U—A Study of its Distribution in the Rat”, Peptides, vol. 8, pp. 779-784, 1987.
NCBI Accession
Berger Claudia
Deleersnijder Willy
Löken Christiane
Nys Guy
Venema Jakob
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Solvay Pharmaceutical B.V.
Ulm John
LandOfFree
Antibodies immunospecific for a novel human G-protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies immunospecific for a novel human G-protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies immunospecific for a novel human G-protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3659917